Sage Therapeutics Inc (NASDAQ: SAGE) on Friday, plunged -5.03% from the previous trading day, before settling in for the closing price of $5.37. Within the past 52 weeks, SAGE’s price has moved between $5.34 and $28.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 3395.58%. The company achieved an average annual earnings per share of 28.43%. With a float of $50.38 million, this company’s outstanding shares have now reached $60.04 million.
Let’s determine the extent of company efficiency that accounts for 487 employees. In terms of profitability, gross margin is 91.75%, operating margin of -349.3%, and the pretax margin is -317.29%.
Sage Therapeutics Inc (SAGE) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Sage Therapeutics Inc is 17.64%, while institutional ownership is 85.08%.
Sage Therapeutics Inc (SAGE) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.55 earnings per share (EPS) for the period topping the consensus outlook (set at -1.29) by 0.74. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.80% during the next five years compared to -2.28% drop over the previous five years of trading.
Sage Therapeutics Inc (NASDAQ: SAGE) Trading Performance Indicators
Sage Therapeutics Inc (SAGE) is currently performing well based on its current performance indicators. A quick ratio of 10.02 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.58, a number that is poised to hit -1.52 in the next quarter and is forecasted to reach -4.06 in one year’s time.
Technical Analysis of Sage Therapeutics Inc (SAGE)
Looking closely at Sage Therapeutics Inc (NASDAQ: SAGE), its last 5-days average volume was 0.73 million, which is a drop from its year-to-date volume of 0.97 million. As of the previous 9 days, the stock’s Stochastic %D was 5.47%. Additionally, its Average True Range was 0.48.
During the past 100 days, Sage Therapeutics Inc’s (SAGE) raw stochastic average was set at 0.83%, which indicates a significant decrease from 1.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 119.05% in the past 14 days, which was higher than the 78.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.96, while its 200-day Moving Average is $12.35. However, in the short run, Sage Therapeutics Inc’s stock first resistance to watch stands at $5.35. Second resistance stands at $5.60. The third major resistance level sits at $5.76. If the price goes on to break the first support level at $4.94, it is likely to go to the next support level at $4.78. Now, if the price goes above the second support level, the third support stands at $4.53.
Sage Therapeutics Inc (NASDAQ: SAGE) Key Stats
Market capitalization of the company is 296.29 million based on 61,173K outstanding shares. Right now, sales total 86,460 K and income totals -541,490 K. The company made 11,870 K in profit during its latest quarter, and -93,550 K in sales during its previous quarter.
